Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Cash (2016 - 2025)

Historic Change in Cash for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $14.3 million.

  • Integra Lifesciences Holdings' Change in Cash rose 1816582.28% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 12907.21%. This contributed to the annual value of -$30.0 million for FY2024, which is 8334.23% up from last year.
  • Integra Lifesciences Holdings' Change in Cash amounted to $14.3 million in Q3 2025, which was up 1816582.28% from -$21.2 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' 5-year Change in Cash high stood at $315.5 million for Q1 2024, and its period low was -$376.7 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Cash was -$79000.0 (2024), whereas its average is -$12.5 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 2073945.21% in 2024, then surged by 1816582.28% in 2025.
  • Integra Lifesciences Holdings' Change in Cash (Quarter) stood at $43.2 million in 2021, then tumbled by 227.9% to -$55.3 million in 2022, then soared by 104.83% to $2.7 million in 2023, then skyrocketed by 1069.21% to $31.2 million in 2024, then plummeted by 54.28% to $14.3 million in 2025.
  • Its Change in Cash was $14.3 million in Q3 2025, compared to -$21.2 million in Q2 2025 and -$7.3 million in Q1 2025.